Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival After Allogeneic HCT in AML Patients Evaluated

Cancer; ePub 2017 Jan 24; Weisdorf, Millard, et al

Publish date:: February 22, 2017

Survival after allogenic hematopoietic cell transplantation (HCT) was best in acute myeloid leukemia (AML) patients who were in second complete remission (CR2), according to a study involving nearly 4,700 individuals with varying disease status. Still, transplants were valuable in some patients in first relapse (Rel1) or primary induction failure (PIF).

Participants all had AML and were in PIF (n=1,440), Rel1 (n=1,256), or CR2 (n=1,986). Investigators looked at survival rates in each group. Among the results:

After adjusting for performance score, cytogenetic risk, and donor type, the 5-year survival rate for CR2 was 39%.
It was 18% in Rel1 and 21% in PIF.

The authors noted that their results can help decide between additional salvage therapy and prompt HCT for patients not in complete remission.

Citation:

Weisdorf D, Millard H, Horowitz M, et al. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. [Published online ahead of print January 24, 2017]. Cancer. doi:10.1002/cncr.30536.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,